Premium
Rapid detection of JMH antibodies with recombinant Sema7A (CD108) protein and the particle gel immunoassay
Author(s) -
Seltsam Axel,
Agaylan Ashraf,
Grueger Daniela,
Meyer Oliver,
Blasczyk Rainer,
Salama Abdulgabar
Publication year - 2008
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2008.01660.x
Subject(s) - recombinant dna , antibody , immunoassay , antigen , streptavidin , flow cytometry , microbiology and biotechnology , agglutination (biology) , chemistry , red blood cell , biology , immunology , biochemistry , biotin , gene
BACKGROUND: At present, identification of antibodies against the high‐prevalence JMH antigen is difficult and limited to reference laboratories having panels of rare red blood cell (RBC) specimens in stock. Here, a novel method is described for detection of anti‐JMH with particles coated with recombinant semaphorin 7A (Sema7A, CD108), the protein that carries the JMH blood group antigens. STUDY DESIGN AND METHODS: Recombinant Sema7A protein was generated and coupled onto superparamagnetic particles coated with streptavidin. The coated particles were tested in the presence of different serum and plasma samples (11 anti‐JMH, 20 other antibodies, and 50 samples from nonimmunized blood donors) with the particle gel immunoassay and flow cytometry. RESULTS: Sema7A‐coated particles reacted with all 11 samples containing anti‐JMH, but not with samples lacking anti‐JMH. In addition, the anti‐JMH agglutination scores were higher with Sema7A‐coated particles than with JMH‐positive RBCs in all cases. CONCLUSION: Recombinant blood group proteins have the potential to replace RBCs as antigen carriers for identification of certain RBC alloantibodies.